The pharmaceutical industry is pushing back against Governor Cuomo's prescription drug price control proposal, arguing that it would lead to cuts in research. And they are pointing the finger at insurance companies and companies known as pharmacy benefit managers for the high costs paid by patients. Peter Pitts is a former FDA Associate Commissioner for External Relations and is now President of the Center for Medicine in the Public Interest.
Pharmaceutical Industry Raises Issue with Cuomo's Drug Price Control Proposal
RECENT NEWS
The coronavirus could help pharma reset its reputation in Washington
The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation in Washington.... Read more
The biggest challenge facing the FDA’s new Rare Disease Innovation Hub
Differing philosophies within and outside of government could doom the hub... Read more
Tort bar’s newest collateral damage: Preterm babies
Lawsuits allege links between intestinal disease, infant formula and human milk fortifiers... Read more